NASDAQ:FATE

Fate Therapeutics - FATE Stock Forecast, Price & News

$23.56

-0.27 (-1.13%)

(As of 10/5/2022 05:11 PM ET)

Add

Compare

Today's Range: $21.89
▼
$23.95
50-Day Range: $21.04
▼
$36.06
52-Week Range: $17.10
▼
$66.56

Volume: 1.17 million shs
Average Volume: 1.44 million shs
Market Capitalization: $2.29 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.46

Fate Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.69 Rating Score
Upside/Downside: 216.3% Upside
$74.46 Price Target
Short Interest: Bearish
22.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 0.49
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.40) to ($4.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

459th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

73rd out of 169 stocks

4.3

Analyst's Opinion

Consensus Rating
Fate Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $74.46, Fate Therapeutics has a forecasted upside of 216.3% from its current price of $23.54.
Amount of Analyst Coverage
Fate Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
22.92% of the float of Fate Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Fate Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.
Change versus previous month
Short interest in Fate Therapeutics has recently increased by 2.77%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Fate Therapeutics does not currently pay a dividend.
Dividend Growth
Fate Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fate Therapeutics is -0.70.

2.5

News and Social Media Coverage

News Sentiment
Fate Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Fate Therapeutics this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,749,685.00 in company stock.
Percentage Held by Insiders
17.34% of the stock of Fate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Fate Therapeutics are expected to decrease in the coming year, from ($3.40) to ($4.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fate Therapeutics is -8.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fate Therapeutics is -8.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fate Therapeutics has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

October 5, 2022 | finance.yahoo.com

Fountain Therapeutics Congratulates Co-Founder and Executive Chairman Thomas Rando, M.D., Ph.D., for Prestigious NOMIS Distinguished Scientist Award

October 5, 2022 | finance.yahoo.com

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

September 28, 2022 | msn.com

10 Things DC Fans Need To Know About Doctor Fate

September 25, 2022 | americanbankingnews.com

Research Analysts Offer Predictions for Fate Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:FATE)

September 14, 2022 | finance.yahoo.com

Fate Therapeutics, Inc. (FATE)

September 8, 2022 | fool.com

Fate Therapeutics (NASDAQ: FATE)

September 8, 2022 | proactiveinvestors.com.au

Chimeric Therapeutics appoints clinical expert Dr Stephanie Astrow VP of translational sciences

September 2, 2022 | finance.yahoo.com

Fate Therapeutics to Participate at Upcoming September Investor Conferences

September 2, 2022 | finance.yahoo.com

Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?

August 23, 2022 | nasdaq.com

Investors might be losing patience for Fate Therapeutics' (NASDAQ:FATE) increasing losses, as stock sheds 20% over the past week

August 18, 2022 | seekingalpha.com

Fate Therapeutics gains as Wells Fargo cites upcoming catalysts

August 9, 2022 | finance.yahoo.com

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

August 9, 2022 | uk.finance.yahoo.com

Natural Killer (NK) Cell Therapeutics Market Research Report 2022

August 4, 2022 | seekingalpha.com

Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

August 4, 2022 | ca.finance.yahoo.com

Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

August 3, 2022 | msn.com

Fate Therapeutics: Q2 Earnings Insights

July 28, 2022 | finance.yahoo.com

Fate Therapeutics Initiated With Hold Rating - Read Why

July 25, 2022 | finance.yahoo.com

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

July 19, 2022 | finance.yahoo.com

Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

July 12, 2022 | finance.yahoo.com

Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock

July 12, 2022 | morningstar.com

North American Morning Briefing: Dollar Cements -2-

July 11, 2022 | markets.businessinsider.com

Expert Ratings for Fate Therapeutics

July 5, 2022 | nasdaq.com

Tuesday's ETF Movers: ARKK, OIH

July 1, 2022 | finance.yahoo.com

Worldwide Natural Killer Cells Therapeutics Industry to 2027 - Featuring Fate Therapeutics, Fortress Biotech and Ziopharm Oncology Among Others

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings: 8/03/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FATE
CUSIP: N/A
CIK: 1434316
Web: www.fatetherapeutics.com
Phone: (858) 875-1800
Fax: N/A
Employees: 449
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $74.46
High Stock Price Forecast: $115.00
Low Stock Price Forecast: $28.00
Forecasted Upside/Downside: +216.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.69
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-212,150,000.00
Net Margins: -371.73%
Pretax Margin: -371.73%
Return on Equity: -40.37%
Return on Assets: -29.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.55
Quick Ratio: 6.55

Sales & Book Value

Annual Sales: $55.85 million
Price / Sales: 40.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.11 per share
Price / Book: 3.31

Miscellaneous

Outstanding Shares: 97,000,000
Free Float: 80,180,000
Market Cap: $2.29 billion
Optionable: Optionable
Beta: 1.69

Key Executives

Mr. J. Scott Wolchko (Age 52)
Founder, CEO, Pres & Director
Comp: $976k

Mr. Edward J. Dulac III (Age 46)
Chief Financial Officer
Comp: $588k

Dr. Mark Plavsic D.V.M. (Age 61)
Ph.D., Chief Technical Officer
Comp: $634.51k

Ms. Cindy R. Tahl (Age 49)
Gen. Counsel & Corp. Sec.
Comp: $602k

Dr. Bahram Valamehr Ph.D. (Age 45)
Chief R&D Officer
Comp: $602k

Dr. Yu-Waye Chu M.D.
Chief Medical Officer

Mr. Jim Beitel M.B.A.
Sr. VP of Corp. Devel.

Dr. Sarah Cooley
Sr. VP of Clinical Translation

Dr. Jerome Bressi Ph.D.
Sr. VP of Regulatory Affairs & Quality

Mr. Brian T. Powl M.B.A.
M.S., Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FATE shares.
View FATE analyst ratings or view top-rated stocks.
What is Fate Therapeutics' stock price forecast for 2022?: 13 brokers have issued twelve-month target prices for Fate Therapeutics' shares. Their FATE share price forecasts range from $28.00 to $115.00. On average, they predict the company's stock price to reach $74.46 in the next twelve months. This suggests a possible upside of 221.2% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.
How have FATE shares performed in 2022?: Fate Therapeutics' stock was trading at $58.51 at the beginning of the year. Since then, FATE stock has decreased by 60.4% and is now trading at $23.18.
View the best growth stocks for 2022 here.
When is Fate Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our FATE earnings forecast.
How were Fate Therapeutics' earnings last quarter?: Fate Therapeutics, Inc. (NASDAQ:FATE) posted its earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07. The biopharmaceutical company had revenue of $18.55 million for the quarter, compared to the consensus estimate of $13.42 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 40.37% and a negative net margin of 371.73%.
What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?: 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).
What is Fate Therapeutics' stock symbol?: Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How do I buy shares of Fate Therapeutics?: Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fate Therapeutics' stock price today?: One share of FATE stock can currently be purchased for approximately $23.18.
How much money does Fate Therapeutics make?: Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $2.25 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.
How many employees does Fate Therapeutics have?: The company employs 449 workers across the globe.
How can I contact Fate Therapeutics?: Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fate Therapeutics - FATE Stock Forecast, Price & News

Fate Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows